v3.26.1
Statement of Changes in Shareholders' Deficit - 10 months ended Dec. 31, 2025 - USD ($)
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Mar. 05, 2025
Balance, shares at Mar. 05, 2025      
Issuance of Class B ordinary shares to Sponsor [1],[2] $ 604 24,396 25,000
Issuance of Class B ordinary shares to Sponsor, shares [1],[2] 6,037,500      
Sale of 638,000 Private Placement Units $ 64 6,379,936 6,380,000
Sale of 638,000 Private Placement Units, shares 638,000        
Fair value of Public Warrants at issuance 1,907,850 1,907,850
Allocated value of transaction costs to Class A shares (141,108) (141,108)
Share-based compensation to director nominees 124,740 124,740
Accretion for Class A ordinary shares to redemption amount (8,295,814) (13,717,066) (22,012,880)
Net income 5,307,942 5,307,942
Balance at Dec. 31, 2025 $ 64 $ 604 $ (8,409,124) $ (8,408,456)
Balance, shares at Dec. 31, 2025 638,000 6,037,500      
[1] On May 14, 2025, the underwriters exercised their over-allotment in full as part of the closing of the Initial Public Offering. As such, the 787,500 Founder Shares are no longer subject to forfeiture (Note 4).
[2] On May 2, 2025, and on May 12, 2025, the Company effected a share capitalization pursuant to which the Company issued an additional 1,725,000 Founder Shares to the Sponsor and the independent director nominees for no additional consideration, resulting in an aggregate of 6,037,500 Founder Shares issued and outstanding. All share and per-share data is retroactively presented (Note 4 and Note 6).